A Randomised phase I/II Trial With Irinotecan, Cetuximab and Everolimus (ICE) Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer.

Trial Profile

A Randomised phase I/II Trial With Irinotecan, Cetuximab and Everolimus (ICE) Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 23 Oct 2015

At a glance

  • Drugs Everolimus (Primary) ; Capecitabine; Cetuximab; Irinotecan; Oxaliplatin
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ICE
  • Most Recent Events

    • 30 May 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology ASCO Annual Meeting 2014.
    • 18 Jan 2014 Primary endpoint 'Progression-free-survival-duration' has not been met.
    • 18 Jan 2014 Results presented at the 2014 Gastrointestinal Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top